Elizabeth Evans
About Elizabeth Evans
Elizabeth Evans is a scientist specializing in mechanistic biology at Adaptimmune, where she has worked since 2021. She has developed expertise in T-cell receptor interactions and has contributed to cancer immunotherapy research.
Work at Adaptimmune
Elizabeth Evans has been employed at Adaptimmune as a Scientist in Mechanistic Biology since 2021. Her role involves contributing to mechanistic biology research, specifically focusing on the interactions of T-cell receptors (TCR) and their therapeutic applications. She participates in cross-functional teams aimed at advancing the company's pipeline of T-cell therapies, playing a significant part in the development of innovative cancer immunotherapy approaches.
Education and Expertise
Elizabeth Evans earned her BSc (Hons) in Biochemistry with Professional Placement from the University of Bath, studying from 2013 to 2017. Her education provided her with a strong foundation in biochemistry, which she has applied in her research. She has developed expertise in mechanistic studies of T-cell receptor interactions, focusing on their implications for therapeutic applications in cancer treatment.
Background
Elizabeth Evans completed her A Levels at The Judd School in Tonbridge, achieving qualifications in Chemistry, Biology, and Maths, along with an AS Level in Latin from 2011 to 2013. Prior to her current position, she worked as a Research Assistant at Animal Health Trust for 10 months in 2015-2016 and as an Associate Scientist in TCR Discovery at Immunocore from 2017 to 2021. Her background includes significant experience in research roles that have contributed to her current expertise.
Achievements
During her career, Elizabeth Evans has contributed to mechanistic biology research at Adaptimmune, focusing on innovative approaches to cancer immunotherapy. Her work has involved the study of T-cell receptor interactions, which are critical for the development of T-cell therapies. Her participation in cross-functional teams has been essential in advancing Adaptimmune's research and development efforts.